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Identifying functionally critical regions of the malaria antigen AMA1 (apical membrane antigen 1) is necessary to
understand the significance of the polymorphisms within this antigen for vaccine development. The crystal structure of
AMA1 in complex with the Fab fragment of inhibitory monoclonal antibody 1F9 reveals that 1F9 binds to the AMA1
solvent-exposed hydrophobic trough, confirming its importance. 1F9 uses the heavy and light chain complementarity-
determining regions (CDRs) to wrap around the polymorphic loops adjacent to the trough, but uses a ridge of
framework residues to bind to the hydrophobic trough. The resulting 1F9-AMA1–combined buried surface of 2,470 A ˚2
is considerably larger than previously reported Fab–antigen interfaces. Mutations of polymorphic AMA1 residues
within the 1F9 epitope disrupt 1F9 binding and dramatically reduce the binding of affinity-purified human antibodies.
Moreover, 1F9 binding to AMA1 is competed by naturally acquired human antibodies, confirming that the 1F9 epitope
is a frequent target of immunological attack.
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Introduction
Malaria is a global health problem that results in up to 3
million deaths annually [1,2]. Most at risk are young children
living in malaria-endemic regions. Older children develop
immunity to the parasite such that there is a reduction in
parasite densities and the associated morbidity and mortality
[3]. Studies demonstrating protection from passive immuni-
zation suggest that a signiﬁcant component of acquired
protective immunity is antibody-mediated [4–6]. Identifying
the antigens recognized by protective immune responses
induced by malaria has been difﬁcult, but many proteins
associated with the merozoite surface or apical organelles are
targets of antibodies that block merozoite invasion.
One such antigen that shows promise as a vaccine
candidate is apical membrane antigen 1 (AMA1). AMA1 is a
type I integral membrane protein with a 55–amino acid
cytoplasmic segment and a 550–amino acid extracellular
region that can be divided into three domains on the basis of
intradomain disulphide bonds [7]. Recombinant AMA1
ectodomain is highly effective at inducing protection in
animal models of human malaria [8,9]. Protection by passive
transfer in mice [10] and the absence of protection in B cell–
deﬁcient mice [11] suggest an important role for the humoral
immune response. Refolded recombinant AMA1 induces
protection, whereas no protection is induced by reduced
and alkylated AMA1 [9,10]. Thus, protection induced by
AMA1 is mediated by antibodies that recognize conforma-
tional epitopes on the surface of the protein. Rabbit and
human anti-AMA1 antibodies have also been shown to
efﬁciently inhibit parasite invasion of erythrocytes in vitro
[12].
Sequencing of P. falciparum AMA1 from laboratory and
ﬁeld strains has produced over 130 non-redundant AMA1
sequences. These sequences result from an assortment of
polymorphisms located throughout the molecule, but con-
centrated in domain I. The population distribution of these
polymorphisms suggests that they have arisen due to
diversifying selection, most likely to avoid the binding of
inhibitory antibodies [13–15]. Consistent with this, protective
responses induced by AMA1 have been shown to be strain-
speciﬁc. Immunization of mice with recombinant P. chabaudi
strain DS AMA1 conferred almost complete protection to
homologous challenge, but little protection to challenge with
the heterologous strain 556KA [9]. Similarly, in in vitro
growth-inhibition studies, P. falciparum strain 3D7 was
efﬁciently inhibited by polyclonal serum elicited by 3D7
AMA1, but the HB3 and W2mef strains were less efﬁciently
inhibited by the same reagent [16]. Kennedy et al. showed that
anti-AMA1 antibodies raised in rabbits inhibited merozoite
invasion by heterologous parasite strains, but there was an
inverse correlation between the degree of inhibition and the
mutational distance of the strains studied [17]. Thus,
inhibitory anti-AMA1 antibodies appear to recognize both
polymorphic and conserved epitopes. AMA1 is currently
being tested in several early clinical trials, and in one of these
trials a combination of 3D7 and FVO AMA1 is being assessed
in an attempt to overcome the problem of polymorphisms in
this antigen [18,19].
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function is still unknown. AMA1 is an unusual malaria
vaccine candidate in that it is required for both merozoite
invasion of erythrocytes [20] and sporozoite invasion of
hepatocytes [21]. AMA1 is targeted to the micronemes of
developing merozoites and is initially expressed as an 83 kDa
precursor protein [22]. N-terminal processing produces a 66
kDa product that is released onto the surface of the free
merozoite [23,24]. At the time of invasion, AMA1 is cleaved by
a membrane-bound subtilisin-like protease, PfSUB2, result-
ing in the shedding of a 48 kDa fragment such that only the
cytoplasmic, transmembrane, and a 29 residue membrane-
adjacent fragment can be detected in ring-stage parasites
[25,26]. The importance of the shedding process is not clear,
but growth inhibitory anti-AMA1 polyclonal sera interfere
with AMA1 shedding such that aberrantly processed forms of
AMA1 are detected [26,27]. AMA1 has been shown not to
contribute to the primary weak interaction between the
merozoite and erythrocyte, but it is involved in secondary
adhesion events which are thought to lead to tight junction
formation immediately prior to host cell invasion [28,29].
Moreover, Toxoplasma gondii AMA1 forms a complex with
proteins, including TgRON4, associated with the tight or
moving junction that propels the parasite into the host cell
[30], and P. falciparum AMA1 has recently been shown to
interact with PfRON4 [31]. The effect of the immune
response on this interaction is unknown.
Crystal structures of AMA1 have revealed that the antigen
contains a pair of closely associated PAN domains [32,33].
Seven loops extend from the PAN scaffold and surround a
long hydrophobic trough [33], which we have speculated is a
ligand-binding pocket. Orthologs of AMA1 have been
identiﬁed in all apicomplexan parasites, with the hydro-
phobic trough conserved across the phylum, including in T.
gondii [34]. Therefore, the evolutionary acquisition of the
loops onto the PAN scaffold that gave rise to the hydrophobic
trough resulted from ancient events that preceded apicom-
plexan parasite divergence. In more recent times, Plasmodium
species have incorporated numerous polymorphisms into
some of these loops. The most highly polymorphic region of
AMA1 surrounds one end of the hydrophobic trough in
domain I, but dimorphic residues extend down one side of
the protein surface into domains II and III [33,35]. This
suggests that the hydrophobic trough is a major target of
protective antibodies, but it is clear that epitopes in other
regions of AMA1 are also recognized by inhibitory antibodies
[27,36,37].
Given that AMA1 is in clinical trials, it is highly desirable to
know more about the antigenic characteristics of the protein.
In particular, information regarding the number and location
of epitopes recognized by inhibitory monoclonal antibodies
will facilitate vaccine development. Two growth-inhibitory
monoclonal antibodies (mAbs) have been characterized: 1F9,
which recognizes a polymorphic epitope on domain I [38,39],
and 4G2, which recognizes a conserved region of domain II
[40]. Mutagenesis studies indicate that their respective
epitopes are located on loops close to but at opposite ends
of the hydrophobic trough [39,40]. Here, by determining the
crystal structure of the complex, we provide a detailed
picture of the 1F9–AMA1 interaction. 1F9 has a very large
footprint on AMA1, which includes hydrophobic trough
residues as well as residues from the surrounding loops. We
also show that mutagenesis of key residues on the loops
surrounding the hydrophobic trough is sufﬁcient to interfere
with mAb 1F9 binding, and that the binding of both 1F9 and
4G2 to AMA1 is competed by naturally acquired human
antibodies. These observations provide evidence in support
of the hypothesis that the hydrophobic trough is an AMA1
ligand-binding site and a major target of protective immun-
ity.
Results
mAb 1F9 Interacts with the AMA1 Hydrophobic Trough
AMA1 domains IþII in complex with 1F9 Fab crystallized
under identical conditions into two crystal forms: crystal
form 1 and crystal form 2, which have been solved to 2.4 and
2.3 A ˚ , respectively (Table 1). An overview of crystal form 1,
the more complete of the two crystal structures, is shown in
Figure 1A. 1F9 interacts exclusively with domain I of AMA1.
The area of interaction encompasses one end of the group of
solvent exposed hydrophobic residues that form part of the
hydrophobic trough (coloured green in Figure 1A), which
may be a ligand-binding site.
The total buried surface area at the 1F9–AMA1 interface is
2,470 A ˚ 2, with 1,250 A ˚ 2 buried on the AMA1 surface and 1,220
A ˚ 2 buried on the 1F9 surface. This is considerably larger than
previously reported Fab–antigen buried surfaces, which
typically range from 600 to 900 A ˚ 2. CDR loops of both the
heavy and light chains of 1F9 interact with AMA1 (Figure 1A
and 1B). In addition to the CDR loops, 1F9 contacts AMA1
using a large area of framework residues, which contact the
hydrophobic trough (Figure 1B). There is, therefore, an
interesting reciprocity to the structure in that the less
variable framework ridge interacts with the conserved
hydrophobic trough, and the variable antibody CDR loops
interact with the polymorphic loops that surround the
trough.
The Principal 1F9 Contact Residues in AMA1 Are
Polymorphic
1F9 covers one-half of the hydrophobic trough and
surrounding loops on the surface of AMA1 (Figure 2A).
Three of the domain I loops (Ic, Id, and Ie) comprise ;90% of
the buried surface on AMA1. The largest interaction is made
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Author Summary
Malaria caused by Plasmodium falciparum causes more than 1
million deaths annually, and the development of a vaccine against
this parasite is a major public health priority. Development of a
vaccine is considered feasible because infection with malaria
parasites induces protective immune responses, which include
antibodies to a range of proteins on the parasite surface. Antigenic
diversity allows the parasite to evade protective responses, and this
may make it difficult to develop a vaccine that is effective against
most infections. To facilitate the design of an effective vaccine, a
more detailed understanding of how antibodies interact with their
target parasite antigens is required. Here, we provide a detailed
structural picture of the interaction between a growth-inhibitory
monoclonal antibody and the leading vaccine candidate, AMA1. The
results provide important insights into why some antibodies are
inhibitory and why antigenic diversity in AMA1 enables the parasite
to evade protective antibody responses.by loop Id, which contributes 48% of the 1F9-covered area.
The four residues that make the largest interactions, E197,
H200, F201, and D204, each contributing ;100 A ˚ 2, are all in
the Id loop (Figure 2B and 2C). All four of these residues are
polymorphic; residues 197 and 200 are highly polymorphic,
residue 201 is less polymorphic, and residue 204 is strictly
dimorphic (Table S1). Other loop residues that make a
signiﬁcant contribution to the 1F9 interface (;80 A ˚ 2) are
dimorphic residue 225 and nonpolymorphic P188 (Figure 2B
and 2C).
Mutations at Polymorphic Sites Abrogate 1F9 Binding
The structure of the 1F9–AMA1 complex is consistent with
point mutants studied previously. Any substitution of E197
abrogated 1F9 binding, whereas mutating several other
polymorphic sites (196, 230, 243, or 244) had no effect on
1F9 binding [39]. The crystal structure shows that residues
243 and 244 do not contact 1F9, whereas 196 and 230 are at
the periphery of the interface where they are solvent-exposed
such that mutations are accommodated (Figure 3A). A further
series of point mutations have been generated in AMA1
domain I expressed on phage. Mutations were introduced at
residues 200, 201, and 204 within loop Id, and residues 225
and 228 within loop Ie; all are sites of frequently occurring
polymorphisms. The residues in 3D7 AMA1 were substituted
with residues occurring in other AMA1 alleles, except for
residue 225, where a conservative I-L mutation was analysed.
Mutations at residues 200, 204, and 225 all abrogated binding
(Figure 3). Substitution of valine for phenylalanine at
position 201 also abrogated binding, whereas the substitution
by leucine at this position only partially abrogated binding.
Similarly, substituting lysine for aspartic acid at position 228
only partially abrogated binding (Figure 3). Deletion of
residues in loop Ic had no effect on 1F9 binding [38]. This
result was surprising because the deleted residues constitute
19% of the AMA1 interaction area. Presumably, because this
area of interaction is at the periphery of the interface,
deletions here can be accommodated. Overall, the mutational
data highlighted the importance of polymorphic residues 197,
200, 201, 204, and 225, and these data were consistent with
the crystal structures in that these residues all present large
1F9-interacting areas.
Molecular Details of the AMA1-1F9 Interface
The principal residues on 1F9 that interact with AMA1 are
derived from light chain CDRs 2 and 3, heavy chain CDR3,
and heavy chain FR1 framework residues, with a minor
contribution from heavy chain CDR1 (Figure 4A). The 1F9
heavy chain CDR3 loop is very short and consists of three
residues (S99, H100, and F101, which form part of a tight type
II’ beta turn), all of which contact AMA1. Heavy chain FR1
framework residues E1 and V2, and G26, F27, and K28, form a
cluster that, together with neighbouring framework residues,
forms a contact surface area of 490 A ˚ 2 (Figure 4A). This
accounts for .50% of the heavy chain interacting surface,
and approximately 40% of the total 1F9 contact area. AMA1
therefore makes contact with a large region on the antibody
surface outside the CDRs that is conserved in most human
and most mouse antibodies.
One half of the 1F9–AMA1 interface is largely polar,
Table 1. Crystallographic Data and Refinement Statistics
Structures Crystal Form 1 (PDB ID: 2Q8A) Crystal Form 2 (PDB ID: 2Q8B)
Data reduction Spacegroup C2 C2
Unit cell (A ˚) 189.8, 51.2, 91.5; 111.18 184.9, 51.5, 95.3; 108.58
Mosaicity 1.38 0.58
Resolution (A ˚) 39–2.4 (2.49–2.40) 28–2.3 (2.38–2.30)
Rsym (percent) 6.1 (23) 5.7 (29)
Completeness (percent) 99.9 (99.9) 99.5 (98.4)
Redundancy 4.0 (3.9) 3.7 (3.7)
I/r 13 (4.7) 14 (4.0)
Refinement statistics (no data cutoff) Reflections (test) 30,851 (1,647) 36,116 (1,899)
Total atoms 5,789 5,598
Waters 247 220
Rcryst (percent) (Rfree) 20.4 (24.5) 20.9 (25.6)
Rms deviations from ideal Bond lengths (A ˚) 0.008 0.008
Bond angles 1.148 1.078
Chiral angles 0.078 0.078
Ramachandran plot* 87.9% core 88.4% core
11.3% allowed 10.8% allowed
0.3% generous 0.3% generous
0.5% disallowed 0.5% disallowed
Average B factor (A ˚2) (B factor without TLS refinement) AMA1 36 (29) AMA1 40 (29)
VL 36 (33) VL 40 (49)
VH 36 (36) VH 40 (45)
CL 35 (59) CL 41 (63)
CH 36 (69) CH 44 (62)
Waters 33 (31) Waters 35 (33)
Data reduction statistics values in brackets are for the outer shell.
aProportion of the molecule within the most favored of disfavored u,w regions determined using PROCHECK [58]. Residues S30, A51 of the light chain, and S99 of the heavy chain have
u,w angles in disallowed regions of the Ramachandran plot. S30 in the light chain CDR1 has u,w angles of 55, 1208 typical of antibodies with the j L1 canonical structure 2A [59]. A51 in
the light chain CDR2 has u,w angles of 72, 368 that are typical of the middle residue of the c turn observed in all L2 structures [59]. S99 (Kabat numbering 95) is part of the heavy chain
CDR3 that forms a type II’ turn. S99 adopts constrained u,w angles of 50, 1208 similar to mean values for the iþ1 position of type II’ beta turns [60].
doi:10.1371/journal.ppat.0030138.t001
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Hydrogen bond interactions observed in both crystal forms
are shown in Figure 4B. Most hydrogen bonds extend from
residues on loop Id. For example, E197 forms hydrogen bonds
with T56 in the light chain CDR2, H200 forms hydrogen
bonds with H100 in the heavy chain CDR3, and D204 forms a
salt bridge with R96 in the light chain CDR3. Mutations at
these three sites (197, 200, 204) disrupted 1F9–AMA1 binding
(Figure 3B), consistent with the importance of these hydrogen
bond interactions at the interface. AMA1 residue N223, which
extends from the domain I PAN helix, hydrogen bonds to D31
in the heavy chain CDR1.
The other half of the AMA1-1F9 interface consists of a
large cluster of hydrophobic side chains (Figure 4C). 1F9
residues in the hydrophobic half of the interface are all part
of the heavy chain. Heavy chain framework residues V2, L4,
and F27 contribute 71, 16, and 86 A ˚ 2, respectively (total 173
A ˚ 2), to the interface. Heavy chain residues T32, L98, and F101
extend from antibody variable regions and contribute 24, 10,
and 80 A ˚ 2, respectively (total 104 A ˚ 2), to the AMA1 interface.
Thus, although conserved framework residues make the
largest contribution to the hydrophobic cluster, variable
residues, in particular F101 in heavy chain CDR3, also
contribute.
Figure 1. Structure of AMA1 in Complex with 1F9 Fab
(A) Alternate views of AMA1 in complex with 1F9 Fab. Backbone trace of 1F9 Fab with the heavy chain coloured orange and the light chain coloured
yellow. Backbone trace of AMA1 (left) or surface view (right) with domain I coloured dark blue and domain II coloured light blue. The AMA1
hydrophobic trough is coloured green. This figure and other figures depicting the structure were generated using PyMOL [56].
(B) Surface representation of the 1F9 Fab bound to AMA1. View of the complex (left), or 1F9 and AMA1 separated (right). Light chain residues that
contact AMA1 (within 4 A ˚) are coloured yellow. Heavy chain residues that contact AMA1 are coloured orange (residues from the CDR loops) or pink
(framework residues). AMA1 residues within 4 A ˚ of 1F9 are coloured dark blue, with the hydrophobic trough residues contacting 1F9 coloured green.
AMA1 loops Ic, Id, and Ie are indicated.
doi:10.1371/journal.ppat.0030138.g001
PLoS Pathogens | www.plospathogens.org September 2007 | Volume 3 | Issue 9 | e138 1311
AMA1-1F9 Fab Crystal StructureAMA1 residues that contribute to the hydrophobic inter-
face cluster include M224, M190, and Y202 from the hydro-
phobic trough (green, Figures 4C and 5A), P188 from loop Ic,
M193 extending from the central PAN beta sheet, and F201 in
loop Id. F201 contributes the largest surface area to the 1F9
interaction (101 A ˚ 2), and P188 also has a large interaction (87
A ˚ 2). Hydrophobic trough residues, M190, Y202, and M224
present smaller surface areas to 1F9 of 40, 24, and 24 A ˚ 2,
respectively, whereas M193 plays a minor role, presenting a
12 A ˚ 2 surface to 1F9. Consistent with its position at the centre
of the hydrophobic cluster, mutations at polymorphic residue
201, were critical for 1F9 binding. Mutating residue 201 to
leucine, 201FL, partially reduced binding, whereas a smaller
subsitution to valine, 201FV, totally disrupted binding (Figure
3B).
Detailed Description of the Hydrophobic Trough
All previously determined structures of AMA1 are incom-
plete, particularly in the loops that surround the hydrophobic
trough. The structure of AMA1-1F9 crystal form 1 is the only
AMA1 structure describing loop If. In addition, the region of
loop II adjacent to the hydrophobic trough is visible, making
this the ﬁrst AMA1 structure that provides a complete view of
the hydrophobic trough (Figure 5A). Previously, nine hydro-
phobic trough residues were deﬁned on the basis of sequence
and surface exposure in the 1Z40 structure [33]. In crystal
form 1, three additional residues have been identiﬁed as
components of the trough. The 12 residues are hydrophobic
in all Plasmodium AMA1 sequences, have hydrophobic side
chains solvent exposed by 7 A ˚ 2 or more, and form part of a
continuous surface on AMA1. The 12 hydrophobic residues
are V169 and L176 on either side of loop Ib, F183 and M190
either side of loop Ic, Y202 and V208 within loop Id, M224 N-
terminal to loop Ie, Y251 and I252 at the centre of the trough
that extends from a loop following PAN beta strand 4 in
domain I, M273 C-terminal side to loop If, and L357 and F367
within loop II (Figure 5A).
1F9 Binding Does Not Significantly Affect the AMA1
Structure
A plot of the distance between alpha carbons in the
overlaid AMA1 structures 1Z40 (AMA1 alone) and AMA1-1F9
crystal form 1 reveals that the overall trajectory of the AMA1
backbone in the two structures is very similar, with root mean
square deviations (rmsds) of less than 1 A ˚ (Figure 5B). The
regions where the rmsd exceeds 1 A ˚ all correspond to the
loops surrounding the hydrophobic trough. The deviations of
loops Ia, Ic, Id, and Ie are not large and rmsds do not exceed
2A ˚ .
The largest variations in the main-chain conformations of
AMA1 among the 1Z40 and AMA1-1F9 crystal form 1 and 2
structures were observed in loop If and loop II. Loops If and
II were largely invisible in AMA1-1F9 crystal form 2, but
where main-chain density was observed, the loop trajectories
differed by 4–8 A ˚ (Figure 5C and 5D). In the 1Z40 structure,
loop II extended up domain I to form a helix and beta-
hairpin adjacent to the hydrophobic trough. Although
sections of loop II were invisible in 1F9–AMA1 crystal form
1, the conformation of the helix-beta-hairpin was identical to
that observed in the 1Z40 structure, with rmsds not exceeding
1A ˚ . Therefore, although loop II can form multiple
conformations, when the loop II helix and beta-hairpin is
observed it forms a precise conformation that packs against
domain I to form part of the hydrophobic trough. Loops Ic
and Id have identical conformations in crystal forms 1 and 2
(Figure 5D), presumably because these loops form a major
part of the AMA1-1F9 interface. In contrast, within loop Ie,
Figure 2. 1F9 Epitope on AMA1
(A,B) Show identical views of the epitope with side chains that interact
with AMA1 with a buried surface area of 7 A ˚2 or more shown in stick form.
(C) Is the same view but showing the surface of the epitope.
(A) Hydrophobic trough residues that contact 1F9 are shown in green with
their residue numbers on either side of the figure. Loops Ic, Id, and Ie and
their 1F9-contacting residues are shown in blue. Side chains that extend
from the PAN domain scaffold and interact with 1F9 are coloured yellow.
(B,C) Principal contact residues. Side chains contacting 1F9 with a surface
area of greater than 78 A ˚2 or more are coloured red. Side chains with a
contact surface area of between 68 and 38 A ˚2 are coloured orange. Side
chains with a contact surface area of between 24 and 7 A ˚2 are coloured
yellow. Surface area interactions were calculated using AREAIMOL [54].
doi:10.1371/journal.ppat.0030138.g002
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AMA1-1F9 Fab Crystal Structureresidue 225 interacts with 1F9 in a consistent manner,
whereas the remainder of the loop adopts a different
conformation in the two crystal forms.
Antibodies from Malaria-Infected Individuals Recognize
the 1F9 Epitope
Polymorphism-scanning mutagenesis and competition
ELISA approaches were used to determine whether the
human immune response to P. falciparum parasites involves
the production of antibodies that resemble 1F9 in their
binding properties. 3D7 AMA1–puriﬁed antibodies were
adsorbed onto plastic and M13 phage expressing 3D7 domain
I were allowed to bind. The conservative substitution 197E-Q,
which had previously been shown to reduce but not ablate
1F9 binding [39], had no discernable effect on the binding of
polyclonal human antibodies (Figure 6A). In contrast, more
radical substitutions (197E-V and 197E-H) dramatically
reduced AMA1 binding to 1F9 and to human antibodies.
E197 hydrogen bonds with T56 in the 1F9 light chain (see
Figure 4B) and the E-Q mutation could preserve these
hydrogen bonds. However, these hydrogen bonds would not
be preserved with valine or histidine substituting for E197.
Also, because of the hydrophobicity of valine and the size and
charge of histidine, these mutations may cause signiﬁcant
pertubations of the surface topology in this region of AMA1.
Mutating polymorphic residues 230 or 243, at either side of
the 1F9 epitope (see Figure 3A), had little effect on the
binding of human antibodies to AMA1 domain I (Figure 6A).
The parallels between the binding of human antibodies and
1F9 to various forms of AMA1 indicate that antibodies
targeting the 1F9 epitope are a component of the human
antibody response to AMA1.
In order to conﬁrm the presence of 1F9-like antibodies in
malaria-infected human plasma, the ability of individual
Figure 3. Effect of AMA1 Mutations on 1F9 Binding
(A) Mapping of point and deletion mutations onto the AMA1 structure. Point mutations at positions 197, 200, 201, 204, and 225 (coloured red)
disrupted 1F9 binding. Point mutations at position 228 (yellow) were partially disruptive. Point mutations at positions 196, 230, 243, and 244 (blue) had
no effect on 1F9 binding. N-terminal deletion of loop Ic (blue) had no effect on binding [38].
(B) M13 phage expressing point mutations in domain I AMA1 were added to immobilized 1F9 at a series of dilutions. Bound phage were assayed by the
addition to peroxidase-conjugated anti-M13 mAb followed by a colourimetric assay. Assays were carried out in duplicate and the error bars indicate the
two measured absorbance values.
doi:10.1371/journal.ppat.0030138.g003
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AMA1-1F9 Fab Crystal StructureFigure 4. 1F9 Recognition Surface and Details of the 1F9–AMA1 Interaction
In all panels AMA1 main chain is coloured yellow, 1F9 light chain is light blue, and 1F9 heavy chain is grey/white.
(A) View of the CDR loops on 1F9. Residues shown are those with an AMA1 contact surface area of at least 35 A ˚2. Light chain CDR2 and 3 side chains are
coloured orange and yellow, respectively, with heavy chain CDR 1 and 3 side chains coloured green and violet, repectively. Residues coloured pink are
in the antibody framework region. Amino acid numbering refers to the 1F9 sequence. In the Kabat numbering scheme [57] heavy chain residue S99 is
S95, H100 is H96, and F101 is F102. Light chain numbering is the same as in the Kabat numbering scheme.
(B) Principal hydrogen bond interactions between AMA1 and 1F9. Side view of the AMA1-1F9 interface showing that most hydrogen bond interactions
occur between AMA1 loop Id (residues 197–204), 1F9 light chain residues and the heavy chain CDR3 (residues S99 and H100). 201O is the main-chain
carbonyl oxygen of residue 201.
(C) View of the 1F9 heavy chain hydrophobic residues sitting in the hydrophobic trough. Hydrophobic trough side chains are coloured green.
doi:10.1371/journal.ppat.0030138.g004
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AMA1-1F9 Fab Crystal Structurehuman plasma to compete with 1F9 for AMA1 binding was
also tested. Plasma (from Papua New Guinean blood donors)
were pre-screened for their ability to recognize recombinant
full-length 3D7 AMA1 ectodomain [12]. Plasma that reacted
strongly with 3D7 AMA1 were tested for their ability to
compete for AMA1 binding with 1F9 and with two other anti-
AMA1 mAbs, 5G8 and 4G2. All six Papua New Guinean
plasma samples reduced the binding of 1F9 to 3D7 AMA1 to
some degree, whereas plasma from individuals with no
exposure to malaria did not inhibit 1F9 binding (Figure
6B). The Papua New Guinean plasma samples also contained
antibodies to the conserved epitope recognized by the
inhibitory antibody 4G2. Only one of the six plasma
contained antibodies to the epitope recognized by the non-
Figure 5. Comparison of Free and 1F9-Complexed AMA1 Structures
(A) Structure of the hydrophobic trough and surrounding loops. Domain
I loops, Ia-If, are shown in dark blue. The domain II loop, II, is shown in
light blue. The 12 hydrophobic trough residues are shown in green with
the label on either side of the figure showing the amino acid and
numbering. I252 and Y251 are not adjacent to loop Ia, but other trough
residue labels are shown next to the loop they are associated with.
(B–D) Comparison of the main-chain trajectories of AMA1 structur-
es.rmsds between superimposed carbon alphas were calculated using
the program LSQKAB [54] and plotted for each residue.
(A) Comparison between AMA1 model 1Z40 and AMA1-1F9 crystal form 1.
(B) Comparison between AMA1 model 1Z40 and AMA1-1F9 crystal form 2.
(C) Comparison between AMA1-1F9 crystal forms 1 and 2. In instances
where residues were missing in either of the compared models the rmsd
was assigned a value of  1.
doi:10.1371/journal.ppat.0030138.g005
Figure 6. Binding of Human Plasma to AMA1
(A) Point mutations abrogate binding of AMA1 domain I to human
antibodies. Phage expressing AMA1 domain I were tested for their ability
to bind to immobilised AMA1-affinty purified human antibodies from a
pool of Papua New Guinean blood donors. Control (black) is M13 phage
expressing strain 3D7 AMA1 domain I. Negative control (grey) is phage
expressing no insert. Point mutations tested were: residue 197E changed
to (H red, Q cyan, V green), or residue 230 K-E (violet), or residue 243 K-N.
Assays were carried out in duplicate and the error bars indicate the two
measured absorbance values.
(B–D) Individual human plasma compete for 1F9 binding to AMA1. Full-
length 3D7 AMA1 ectodomain was immobilised on plastic. MAbs 1F9 (A),
4G2 (B), and 5G8 (C) were allowed to bind and the ability of a set of
human plasma to compete for mAb binding was tested: plasma P8
(green), plasma P45 (pink), plasma P60 (red), plasma P69 (light blue),
plasma P111 (orange), and plasma M157 (grey). Pooled plasma derived
from a malaria unexposed individuals served as a negative control
(black). Assays were carried out in duplicate and error bars indicate the
two measured absorbance values.
doi:10.1371/journal.ppat.0030138.g006
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N-terminus of AMA1, which is not present on the 66 kDa
processed form of the antigen [22,38,39].
The reverse competition experiment, in which the binding
of human antibodies to AMA1 was competed by excess 1F9,
indicated that human antibodies recognizing the 1F9 epitope
are relatively abundant (up to 40% of the total AMA1
reactivity) in the plasma of some individuals (Figure S1). This
result is consistent with the AMA1 domain 1 mutagenesis
experiment, suggesting that the 1F9 epitope is an important
target of the human anti-AMA1 antibody response in
individuals exposed to malaria.
Discussion
The crystal structures described here show that mAb 1F9,
which inhibits merozoite invasion, interacts with an epitope
on AMA1 that includes residues in the hydrophobic trough
and on loops surrounding the trough. This is consistent with
the hypothesis that the hydrophobic trough is a ligand-
binding pocket that plays an essential role in merozoite
attachment and/or invasion. The residues presenting the
largest surface area to 1F9 are located on the loops
surrounding the hydrophobic trough. Most of these residues
are polymorphic, and mutagenesis conﬁrmed that they are
critical to 1F9 binding, consistent with the parasite strain
speciﬁcity observed for 1F9-mediated inhibition [39]. This
contrasts with the epitope of the non-inhibitory mAb
F8.12.19, which is located in domain III and conserved in
several plasmodial species [41].
The 1F9–AMA1 interface is unusual in that the buried
surface area is very large and antibody framework residues
make extensive contact with the antigen. These framework
residues form a ridge that protrudes into the hydrophobic
trough, giving complementary surfaces unlike most antibody/
protein interfaces, which are typically ﬂat [42]. Exceptions
include antibodies with long heavy chain CDR3 loops such as
mAb b12, where the CDR3 protrudes into the CD4 binding
site of HIV gp120 [43]. The 1F9 heavy chain CDR3 loop is very
short and, as a result, recessed such that neighbouring
framework residues are exposed. These residues from heavy
chain FR1 are commonly found in mouse and human
antibodies apart from residue 26, which appears to have
resulted from an N to K somatic mutation (Figure S2). The
ridge framework residues, together with a short CDR3 loop,
may allow antibodies to interact with antigens possessing
clefts. Consistent with this, framework residues of the
neutralizing mAb 17-IA make important contacts with a
receptor-binding canyon on human rhinovirus 14 [44].
Serological studies indicate that a signiﬁcant proportion of
the human antibody response to AMA1 is directed towards
polymorphic epitopes [45,46]. The 1F9 epitope encompasses
the most polymorphic surface region of AMA1, and human
antibodies compete with 1F9 for binding to full-length
recombinant AMA1. These observations suggest that that
the region containing the 1F9 epitope may be an antigenic
hot-spot. Residue 197, on loop Id, is the most polymorphic
site in AMA1 and appears to be a critical residue in this
dominant epitope, as mutation of this residue not only
ablates 1F9 binding, but also markedly reduces the binding of
human antibodies. In an initial attempt to quantify the
antigenicity of the 1F9 epitope, the ability of 1F9 to compete
for human plasma was tested. These preliminary experiments
suggest that in some, but not all, individuals, a signiﬁcant
fraction of anti-AMA1 antibodies bind to the 1F9 epitope
region (Figure S1).
It is not suprising that the unusual AMA1 loops are targets
of the antibody binding given their surface exposure and
ﬂexibility [47]. The loops surrounding the hydrophobic
trough in the region of the 1F9 epitope are moderately
ﬂexible, whereas loops II and If are considerably more
ﬂexible. It would be anticipated that antibodies binding to
the region of the trough surrounded by the more ﬂexible
loops would be parasite-growth inhibitory, and, indeed,
inhibitory mAb 4G2 is known to bind to loop II [40]. In
contrast to the loops contributing to the 1F9 epitope, loops II
and If contain very few polymorphisms. Loop II has no
polymorphisms and loop If only has two polymorphic sites:
267, with conservative substitutions (glutamate or glutamine),
and residue 273, which is mostly lysine with isoleucine
occurring at a low frequency. Thus, there is a striking
difference in the abundance of polymorphisms in the various
loops surrounding the hydrophobic trough, and this is
inversely correlated with loop ﬂexibility. It is not clear why
the more ﬂexible loops are less polymorphic, but they border
the non-polymorphic face of AMA1, and this face may be
partially hidden on the parasite surface. Consistent with this,
4G2 is known to be a more effective inhibitor as the Fab
fragment [27]. Flexibility itself may offer partial antigenic
‘‘protection,’’ or there may be other ﬁtness constraints that
prevent mutations within the ﬂexible loops.
Antibodies to AMA1 could inhibit merozoite invasion by
several mechanisms. For example, it has been reported that
inhibitory antibodies block AMA1 processing events [27]. On
the basis of the information presented here, a reasonable
conclusion is that 1F9 inhibits merozoite invasion by blocking
the access of a ligand to the hydrophobic trough. Although
the 4G2 epitope has been mapped to the opposite face of
AMA1, its epitope also lies adjacent to the hydrophobic
trough. It is therefore likely that these different monoclonal
antibodies inhibit merozoite invasion through a common
mechanism.
A hydrophobic trough-binding ligand has not been
identiﬁed, but AMA1 is known to be associated with a
rhoptry neck protein RON4 that is part of the moving
junction between the surface of the invading merozoite and
the erythrocyte membrane [30,31]. The nature of the
interaction between RON4 and AMA1 is not understood;
however, if the hydrophobic trough is involved in binding, it
is unclear how antibodies would interfere with the AMA1/
RON4 association if surface exposure of the complex is
limited to the moving junction.
The polymorphic nature of merozoite surface proteins is a
major problem confronting the development of a malaria
vaccine incorporating one or more of these antigens. In a
vaccine trial in Papua New Guinea, a three-component
vaccine containing one form of MSP2 reduced parasite
densities, but the effect was restricted to parasites expressing
MSP2 genotypes of the same dimorphic form as the vaccine
component [48]. AMA1 lacks the highly polymorphic repet-
itive sequences seen in MSP2, but close to 10% of the residues
in the ectodomain are polymorphic. Consequently, large
numbers of AMA1 haplotypes occur in endemic areas [13–15],
and a vaccine incorporating a single allelic form of AMA1 is
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falciparum genotypes.
Given the number of alternative amino acid residues that
are found in the 1F9-binding region, it seems unlikely that
the strategy of combining two forms of AMA1 (3D7 and FVO)
[19] will result in a vaccine that, acting alone, induces
effective titres of antibodies to this polymorphic site on the
majority of P. falciparum genotypes. In the context of endemic
malaria, such a vaccine may still achieve a satisfactory level of
efﬁcacy because many infections are avirulent, and these have
the potential to broaden the speciﬁcity of the immune
response primed by the vaccine. These considerations under-
line the importance of analyzing the genotypes of break-
through parasitemias in vaccine trials. If an AMA1 vaccine
containing one or two forms of the antigen only protects
against a minority of parasite genotypes, an alternative
strategy may be to generate a form of AMA1 that targets
the immune response to conserved regions of the molecule,
including the ‘‘non-polymorphic’’ end of the hydrophobic
trough. A potential strategy to achieve this may be to
construct a form of AMA1 in which the polymorphic loops
are removed or truncated.
Materials and Methods
Fab 1F9 production, sequencing, crystallization, and data collec-
tion. AMA1 domains IþII were expressed in E. coli and refolded and
puriﬁed using procedures described previously [49]. Mouse mAb 1F9
(isotype IgG2b with a Kappa light chain) was produced in hybridoma
cell cultures and puriﬁed by protein G afﬁnity chromatography. 10
mg of 1F9 was digested with 2.25 mg papain (Sigma) in 26 mM tris
(pH 7.5), 4 mM EDTA, 4 mM 2-mercaptoethanol for 3 h at 20 8C.
Proteolysis was terminated by adding 100 mM iodoacetic acid for 1 h
at 4 8C. The 1F9 Fab fragment was puriﬁed by cation exchange
chromatography (Mono S) in 20 mM acetic acid–NaOH (pH 5.0),
eluting at 100 mM NaCl. The fragment was further puriﬁed by size
exclusion chromatography (Hi Prep sephacryl S-200) in 20 mM acetic
acid–NaOH (pH 5.0). The puriﬁed protein was dialysed into water,
concentrated to 10 mg/ml, and stored at 4 8C in 0.02% sodium azide.
For crystallization, AMA1 domains IþII and 1F9 Fab were mixed
(with the Fab in slight excess) and added to well solution (20 mM MES
[pH 6.0], 10 mM MnCl2, 6% PEG 3350). Crystallization was carried by
vapour diffusion in hanging drops and yielded two crystal forms that
grew within 5 days. Both crystal forms were stabilized in 20 mM MES
(pH 6.0), 10 mM MnCl2, 10% PEG 3350 for manipulations, and
momentarily suspended in stabilization solution plus 25% methyl-
petanediol or glycerol for cryofreezing. The crystals were maintained
at 100 K and data collected in-house using a rotating anode generator
and image plate detector. 1808 of data was collected in 0.58 sections
and indexed using D*TREK [50].
1F9 heavy and light chain variable domain sequences were
determined following the method of Gilliland et al. [51]. Sequences
are shown alongside the closest matching mouse genomic sequences
in Figures S2 and S3.
Structure determination and reﬁnement. The structures were
solved by molecular replacement with PHASER [52] using P.
falciparum AMA1 structure 1Z40 [33] and mouse IgG2b/Kappa Fab
structure 2CGR [53]. AMA1-1F9 complex structures were reﬁned
using REFMAC5 [54] and model building carried out using O [55].
The structures were divided into 5 TLS groups: AMA1, the light
variable domain, the light constant domain, the heavy variable
domain, and the heavy constant domain.
In crystal form 2, the domain II loop is disordered and AMA1
residues A355–A387 were not observed in the electron density.
Similarly, the domain I loop, If, was disordered (AMA1 residues
A264–A272). There was one gap in the heavy chain constant domain
between residues H128 and H132. In crystal form 1, there were two
gaps in the AMA1 structure. Both of these gaps were in the domain II
loop: A351–A353 and A377–A389. In addition, there were two
electron density gaps in the heavy chain constant domain: residues
H128–H131 and H155–H159.
AMA1 expression on phage, mutagenesis, and 1F9 binding. AMA1
mutations were generated using the Kunkel method as described
previously [39]. Mutated fragments were inserted into phagemid
vector pHENH6 and AMA1-expressing phage were generated by
inoculating transformants with M13KO7 helper phage. Phage
preparations were normalized for AMA1 expression by performing
ELISAs to examine the binding of mAb 9E10 to a C-terminal c-Myc
epitope. 1F9 binding was examined by binding phage to immobilized
1F9 and detected using peroxidise conjugated anti-M13 mAb
followed by colourimetric assay and measurement of light absorbance
at 450 nm [39].
Competition ELISAs. 100 ll of 0.3 lg/ml of full-length AMA1
ectodomain was immobilized on plastic. 100 ll dilutions of human
plasma from Papua New Guinean blood donors (previously selected
for reactivity to a series of malaria antigens, including full-length 3D7
AMA1 ectodomain) was added followed by 10 ll of 3.0 lg/ml mAb
(either 1F9, 5G8, or 4G2). The ELISA plate was washed, peroxidase-
conjugated anti-mouse antibodies added, and the assay developed.
For reverse competition experiments, plasma was added prior to
mAbs, and peroxidase-conjugated anti-human antibodies added to
the washed plate.
Supporting Information
Figure S1. 1F9 Competes with Human Plasma for Binding to AMA1
Full-length 3D7 AMA1 ectodomain was immobilised on plastic and
bound to individual human plasma: serum P8 (green), serum P45
(pink), serum P111 (orange), and serum M157 (grey).
(A) Ability of mAb 1F9 to compete for plasma was tested by adding
1F9 to AMA1 immediately prior to the addition of plasma.
(B) Competition experiment with mAb 4G2. The observed lack of
competition does not necessarily indicate a low human antibody
response to the 4G2 epitope region and may result from a low afﬁnity
of 4G2 for AMA1, consistent with the enhanced ability of human
antibodies to compete for 4G2 (Figure 6C). The increased signal at
high 4G2 concentrations may be due to cross-reactivity between 4G2
and the conjugated anti-human reagent. Alternatively, binding of
4G2 may induce conformational changes such that there is an
increase in binding of human antibodies to neighbouring epitopes.
Found at doi:10.1371/journal.ppat.0030138.sg001 (1.4 MB PDF).
Figure S2. 1F9 Heavy Chain Sequence
The VH sequence is the closest matching mouse germline heavy chain
variable gene (Genebank accession number X03571). D? is the short
sequence, ctttccc, attributable to a D sequence, but showing no
homology to any of the mouse D minigenes. 1F9 utlizes the mouse
heavy chain J2 minigene (accession number X63166). CH1 sequence is
part of the heavy chain gamma-2b C-region (accession number
L00051). Somatic mutations are highlighted in pink. Sequences
shown in blue are recombination recognition sequences and introns
that are not present in the mRNA. 7 mer and 9 mer refer to the
recombination recognition motifs that are capitalized. Variable
antibody CDR sequences are underlined. Numbers in green indicate
the area of interaction with AMA1 in crystal form 2. Underlined areas
indicate a hydrogen bond interaction with AMA1. Arrows indicate
stretches of beta strand and the cylinder an alpha helix.
Found at doi:10.1371/journal.ppat.0030138.sg002 (44 KB PPT).
Figure S3. 1F9 Light Chain Sequence
VL is the closest matching mouse variable kappa light chain gene,
IgVk19–32 (accession number AJ235968). 1F9 light chain uses the
kappa J2 minigene (accession number L80040). CL is part of the
kappa light chain constant genes e q u e n c e( a c c e s s i o nn u m b e r
V01569).
Found at doi:10.1371/journal.ppat.0030138.sg003 (40 KB PPT).
Table S1. Polymorphisms within the 1F9 Epitope
Table of AMA1 residues that contact 1F9 showing the polymorphisms
in the ﬁeld, and the polymorphic difference probability (the
probability that two sequences differ at a position). Table S1 also
shows the 1F9-buried surface for each AMA1 residue in crystal form
2. Polymorphic residues tend to be more exposed and present a
larger surface area to 1F9.
Found at doi:10.1371/journal.ppat.0030138.st001 (43 KB DOC).
Accession Numbers
The Protein Data Bank (http://www.rcsb.org/pdb/) ID numbers for the
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AMA1-1F9 Fab Crystal Structurestructures discussed in this paper are crystal form 1 (2Q8A) and
crystal form 2 (2Q8B).
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